Business / Finance

RSS

ImaginAb announces completion of $21M Series B financing

ImaginAb, Inc., a clinical stage biotechnology company that engineers antibodies into smaller protein formats optimized for in vivo molecular imaging, announced today the completion of a $21M Series B financing of the company, led by Mérieux Développement and syndicated with Novartis Venture Funds, Cycad Group and Nextech Invest.

9 May 2014

Dyadic International's total revenue for Q1 2014 up 20%

Dyadic International, Inc., a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and others proteins for the bioenergy, bio-based chemicals, biopharmaceutical and industrial enzyme industries, today announced financial results for the first quarter ended March 31, 2014.

8 May 2014

NxStage Medical reports revenue of $72.2 million for first quarter 2014

NxStage Medical, Inc., a leading manufacturer of innovative dialysis products, today reported record first quarter financial results that exceed the top end of its guidance range.

8 May 2014

IPM gains exclusive worldwide rights to promising HIV prevention medicine from Janssen R&D Ireland

The International Partnership for Microbicides announced today that it has received exclusive worldwide rights to a promising HIV prevention medicine called dapivirine from Janssen R&D Ireland, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

8 May 2014

MAXIMUS revenue increases 35% to $439.0 million in second quarter fiscal 2014

MAXIMUS, a leading provider of government services worldwide, today reported financial results for the three and six months ended March 31, 2014.

8 May 2014

Kindred's consolidated revenues increase 2% to $1.30 billion in Q1 2014

Kindred Healthcare, Inc. today announced its operating results for the first quarter ended March 31, 2014.

7 May 2014

Ligand's total revenues increase 37% to $16.0 million in first quarter 2014

Ligand Pharmaceuticals Incorporated today reported financial results for the three months ended March 31, 2014, and provided an operating forecast and program updates.

7 May 2014

Rigel Pharmaceuticals reports net loss of $22.3 million for first quarter 2014

Rigel Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2014.

7 May 2014

Streamline Health Solutions inks definitive agreement to acquire all assets of CentraMed

Streamline Health Solutions, Inc., a leading provider of transformational data-driven solutions to help healthcare providers reduce exposure to risk, enhance clinical, financial, and operational performance, and improve patient care, today announced that the Company has signed a definitive agreement to acquire substantially all of the assets of CentraMed, Inc.

7 May 2014

Gentiva’s net revenues increase $487.5M to 17% in Q1 2014

Gentiva Health Services, Inc., one of the largest providers of home health, hospice and community care services in the United States, today reported first quarter 2014 results.

7 May 2014

HOYA’s revenues increase 19.9% to 115,224 million yen in Q4 2014

HOYA Corporation today announced financial results for the fourth quarter and full-year ended March 31, 2014. During the quarter, revenues increased 19.9% to 115,224 million yen compared with the same period last year.

7 May 2014

Evogene reports operating loss of $2.6M in first quarter 2014

Evogene Ltd., a leading plant genomics company specializing in enhancing crop productivity for the food, feed and biofuel industries, announced today its financial results for the quarter ended March 31, 2014.

7 May 2014

Phillips-Medisize enters into definitive agreement with Golden Gate Capital

Phillips-Medisize Corporation today announced that it has entered into a definitive agreement under which Golden Gate Capital will acquire the Company from funds managed by Kohlberg & Company, L.L.C.

7 May 2014

Targacept reports net loss of $11.6M in first quarter 2014

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today reported its financial results for the first quarter ended March 31, 2014.

7 May 2014

ARIAD provides update on corporate developments, reports Q1 2014 financial results

ARIAD Pharmaceuticals, Inc. today reported financial results for the first quarter of 2014, including revenue from sales of Iclusig® (ponatinib) and licensing agreements. The Company also provided an update on corporate developments.

7 May 2014

Humana reports EPS of $2.35 in Q1 2014; confirms EPS guidance for FY14

Humana Inc. today reported diluted earnings per common share (EPS) for the quarter ended March 31, 2014 (1Q14) of $2.35, compared to diluted earnings per common share (EPS) of $2.95 for the quarter ended March 31, 2013 (1Q13).

7 May 2014

ArQule reports net loss of $7,141,000 in first quarter 2014

ArQule, Inc. today announced its financial results for the first quarter of 2014. For the quarter ended March 31, 2014, the Company reported a net loss of $7,141,000 or $0.11 per share, compared to a net loss of $5,775,000, or $0.09 per share, for the first quarter of 2013.

7 May 2014

Vestagen partners with Scrubs to distribute Vestex protective fabrics

Vestagen Technical Textiles, Inc., today announced that it has entered into agreements with Scrubs AC, Inc., d/b/a allheart, to produce and distribute protective garments for the healthcare sector manufactured using Vestagen's Vestex® protective fabric.

7 May 2014

IASIS Healthcare's net revenue increases 7.7% to $648.1 million in second quarter fiscal 2014

IASIS Healthcare LLC today announced financial and operating results for the fiscal second quarter and six months ended March 31, 2014.

6 May 2014

Loxo Oncology announces closing of $24 million Series B private financing round

Loxo Oncology, Inc., a biopharmaceutical company focused on developing targeted cancer therapies for genetically-defined populations, announced today that it has closed a $24 million Series B private financing round led by New Enterprise Associates.

6 May 2014